MGF (mechano growth factor) is a research-only peptide with no approved human dosing. The pattern below is commonly cited and anecdotal — not medically established. It is provided for education, not as a personal protocol.
Overview
MGF is a short, locally acting splice variant of IGF-1. There is no regulator-approved schedule, so any figures come from community reports rather than clinical data. Its very short duration is the defining practical feature — the reason the pegylated variant (PEG-MGF) exists.
Commonly cited pattern
Reported figures vary and should be treated as unverified:
- Commonly cited amounts are low — in the microgram range — often described as given near a targeted muscle group.
- Because native MGF is short-lived, community sources often describe frequent, locally placed injections rather than a single systemic dose.
- These numbers are anecdotal and not medically established; there is no validated schedule.
No figure here should be read as a recommended or validated amount.
How it is administered
In research settings, MGF is supplied as a lyophilized powder and reconstituted with bacteriostatic water before subcutaneous injection.
- The delivered amount depends on reconstitution and on reading syringe units as volume — a frequent source of dosing errors, especially at microgram amounts.
- Sterility and cold storage matter, since the peptide degrades with heat, light, and freeze-thaw.
Why timing and locality matter
Native MGF is generally described as rapidly degraded and locally acting. That short duration is precisely why PEG-MGF was developed to extend circulation time. Reasoning about MGF therefore emphasizes its transient, local character rather than a fixed schedule.
Why oversight matters
MGF has no approved label, defined contraindications, or monitoring framework, so there is no consumer-safe amount to generalize from. Any decision to use it, if at all, belongs within controlled research under qualified supervision.